Investigating effects of aspirin in people with venous leg ulcers: The ASPiVLU randomised controlled trial

Research output: Contribution to journalArticleOtherpeer-review


Background: Venous leg ulcers (VLUs) are a common problem that impact on quality of life and are a costly health care burden. Cost-effective strategies to heal and prevent recurrence are required to address this growing burden. Whilst compression therapy has the potential to heal some ulcers, new treatments are needed to address those wounds that are more challenging to heal. Targeting the inflammatory processes underlying venous ulcers is a possible strategy. Limited evidence suggests that low-dose aspirin may be an effective adjunct to aid ulcer healing and reduce recurrence. The Aspirin in Venous Leg Ulcer study (ASPiVLU) will seek to investigate if daily low-dose aspirin improves time to healing.

Design: This randomised, double-blinded, multicentre, placebo-controlled clinical trial will recruit 268 participants with a chronic VLU from wound clinics across Australia. Participants will be randomised to receive either daily oral aspirin (300 mg) or placebo, in addition to best practice compression therapy.

Discussion: This study will provide a robust evaluation of the benefits and harms of aspirin as an adjunct therapy to compression in the management of VLUs. Recruitment commenced in March 2015 and study completion is anticipated in June 2018.
Original languageEnglish
Pages (from-to)70 - 74
Number of pages4
JournalWound Practice and Research
Issue number2
Publication statusPublished - Jun 2015

Cite this